Sinomenine

CAT:
804-HY-15122-01
Size:
100 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Sinomenine - image 1

Sinomenine

  • Description :

    Sinomenine, an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation[1]. Sinomenine also is an activator of μ-opioid receptor[2].
  • UNSPSC :

    12352005
  • Hazard Statement :

    H302, H315, H319, H335
  • Target :

    Apoptosis; Autophagy; NF-κB; Opioid Receptor
  • Type :

    Natural Products
  • Related Pathways :

    Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; NF-κB
  • Applications :

    Cancer-programmed cell death
  • Field of Research :

    Cancer; Inflammation/Immunology; Neurological Disease
  • Assay Protocol :

    https://www.medchemexpress.com/sinomenine.html
  • Concentration :

    10mM
  • Purity :

    99.96
  • Solubility :

    1M HCl : 25 mg/mL (ultrasonic; adjust pH to 1 with HCl) |DMSO : 50 mg/mL (ultrasonic)
  • Smiles :

    OC(C1=C2C[C@@]3([H])[C@](C=C4OC)([H])[C@@]1(CCN3C)CC4=O)=C(C=C2)OC
  • Molecular Formula :

    C19H23NO4
  • Molecular Weight :

    329.39
  • Precautions :

    H302, H315, H319, H335
  • References & Citations :

    [1]Song L, et al. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun. 2015 Aug 28;464 (3) :705-10.|[2]Gao T, et al. Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol. 2013 Dec 5;721 (1-3) :5-11.|[3]Zhu Q, et al. Antinociceptive effects of sinomenine in a rat model of neuropathic pain. Sci Rep. 2014 Dec 1;4:7270.|[4]Wang MH, et al. Activation of opioid mu-receptor by sinomenine in cell and mice.Neurosci Lett. 2008 Oct 10;443 (3) :209-12.
  • Shipping Conditions :

    Room Temperature
  • Storage Conditions :

    4°C (Powder, protect from light)
  • Scientific Category :

    Natural Products
  • Clinical Information :

    Launched
  • Isoform :

    μ Opioid Receptor/MOR
  • Citation 01 :

    Acta Pharm Sin B. 2021 Nov;11 (11) :3465-3480.|Chem Biol Drug Des. 2023 Sep;102 (3) :434-443.|Drug Des Devel Ther. 2024 Aug 6:18:3523-3545.|Exp Ther Med. 2021 Jun;21 (6) :647.|Heliyon. 2024 Jun 24;10 (13) :e33314.|J Inflamm Res. 2023 Oct 20:16:4777-4791.|Naunyn Schmiedebergs Arch Pharmacol. 2025 May 17.|Phytomedicine. 2025 May:140:156484.|Phytother Res. 2023 Aug;37 (8) :3323-3341.|PLoS Biol. 2024 Jun 27;22 (6) :e3002672.|World J Stem Cells. 2024 May 26.|bioRxiv. 2024 Apr 3:2023.06.02.542933.|Free Radic Biol Med. 2018 Aug 20:124:205-213.|Immun Inflamm Dis. 2024 Jun;12 (6) :e1271.|J Dairy Sci. 2025 Nov 7:S0022-0302 (25) 00911-7.
  • CAS Number :

    [115-53-7]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide